Ashutosh Lal, MD

Title(s)Professor, Pediatrics
SchoolSchool of Medicine
Address35 Medical Center Way, #903D
San Francisco CA 94143
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    I am a hematologist at UCSF Benioff Children’s Hospital Oakland, Director of Clinical Hematology, and Director of the Comprehensive Thalassemia Center and Iron Disorders Program. I spend 50% time in clinic and 50% in research. My long-term academic and clinical interests are thalassemia, iron overload, and nutrition. The Thalassemia Program in Oakland is the largest clinical program in the country managing over 300 active patients. My research portfolio extends from natural history studies, molecular diagnostics, iron quantification, micronutrient deficiencies, to clinical trials in iron chelation, new disease-modifying agents, and gene therapy for beta thalassemia. My center is supported by HRSA and CDC to study the prevalence and complications of thalassemia in the U.S. and to develop evidence-based standards care for thalassemia. I am the coordinator of the Thalassemia Western Consortium, an association of twelve academic hematology programs in the western states, to improve training and management of thalassemia care. Alpha thalassemia is a special emphasis area where we have delineated the genotype-phenotype relationship in alpha thalassemia, published international guidelines for managing HbH disease, postnatal care of alpha thalassemia major. I am invested in the development of gene therapy approaches to severe forms of thalassemia. I provide consultation and care for complex iron overload in non-hematological conditions in children and adults.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sustained Efficacy and Safety in Adult and Pediatric Patients with Transfusion-Dependent ß-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel). Transplantation and Cellular Therapy. 2024 Feb 1; 30(2):s230. Walters WM, Thompson TA, Olson OT, Porter PJ, Schneiderman SJ, Hongeng HS, Kulozik KA, Cavazzana CM, Sauer SM, Thrasher TA, Thuret TI, Lal LA, Rasko RJ, Yannaki YE, Ali AS, Tao TG, Thakar TH, Deora DA, Gruppioni GK, Colvin CR, Locatelli LF, Kwiatkowski KJ. .
      View in: Publisher Site   Mentions:
    2. Sustained Efficacy, Safety, and Improved Quality of Life in Adult and Pediatric Patients with Transfusion-Dependent ß-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel). Blood. 2023 Nov 28; 142(Supplement 1):1102. Thompson TA, Olson OT, Walters WM, Porter PJ, Schneiderman SJ, Hongeng HS, Kulozik KA, Cavazzana CM, Sauer SM, Thrasher TA, Thuret TI, Lal LA, Rasko RJ, Yannaki YE, Ali AS, Tao TG, Thakar TH, Deora DA, Gruppioni GK, Colvin CR, Locatelli LF, Kwiatkowski KJ. .
      View in: Publisher Site   Mentions:
    3. Improvement in Iron Burden in Patients with Transfusion-Dependent ß-Thalassemia (TDT) Treated with Betibeglogene Autotemcel (Beti-cel) Gene Therapy: Up to 9 Years of Follow-up. Blood. 2023 Nov 28; 142(Supplement 1):2480. Kwiatkowski KJ, Olson OT, Walters WM, Porter PJ, Schneiderman SJ, Hongeng HS, Kulozik KA, Cavazzana CM, Sauer SM, Thrasher TA, Thuret TI, Lal LA, Rasko RJ, Yannaki YE, Ali AS, Tao TG, Deora DA, Thakar TH, Colvin CR, Locatelli LF, Thompson TA. .
      View in: Publisher Site   Mentions:
    4. Pharmacokinetics (PK) of Deferasirox in Transfusion Dependent Thalassemia. Blood. 2023 Nov 28; 142(Supplement 1):5248. Winger WB, Usac UF, Huang HL, Lal LA, Long-Boyle LJ. .
      View in: Publisher Site   Mentions:
    5. The Clinical Phenotypes of Alpha Thalassemia. Hematol Oncol Clin North Am. 2023 04; 37(2):327-339. Lal A, Vichinsky E. PMID: 36907606.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. 385 Long-term Outcomes of 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed-up to 7 Years after Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy (GT) and Factors Impacting Neutrophil and Platelet Engraftment. Transplantation and Cellular Therapy. 2023 Feb 1; 29(2):s291-s292. Olson OT, Walters WM, Kwiatkowski KJ, Porter PJ, Schneiderman SJ, Hongeng HS, Kulozik KA, Cavazzana CM, Sauer SM, Thrasher TA, Thuret TI, Lal LA, Rasko RJ, Yannaki YE, Ali AS, Colvin CR, Locatelli LF, Thompson TA. .
      View in: Publisher Site   Mentions:
    7. Long Term Outcomes of 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials. Blood. 2022 Nov 15; 140(Supplement 1):5355-5357. Walters WM, Kwiatkowski KJ, Porter PJ, Schneiderman SJ, Hongeng HS, Kulozik KA, Cavazzana CM, Sauer SM, Thrasher TA, Thuret TI, Lal LA, Rasko RJ, Yannaki YE, Ali AS, Shestopalov SI, Fincker FM, Colvin CR, Whitney WD, Locatelli LF, Thompson TA. .
      View in: Publisher Site   Mentions:
    8. Mitapivat Improves Markers of Erythropoietic Activity in Long-Term Study of Adults with Alpha- or Beta-Non-Transfusion-Dependent Thalassemia. Blood. 2022 Nov 15; 140(Supplement 1):2479-2480. Kuo KK, Layton LD, Lal LA, Al-Samkari AH, Kosinski KP, Tong TB, Estepp EJ, Uhlig UK, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    9. PSUN160 Transfusion Related Endocrinopathies and Thalassemia (TREAT) Study. Journal of the Endocrine Society. 2022 Nov 1; 6(Suppl 1):a443-a443. Erkin-Cakmak EA, Ahmad AT, Rishon RA, Weyhmiller WM, Fung FE, Lodish LM, Lal LA. .
      View in: Publisher Site   Mentions:
    10. LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA. Hematology Transfusion and Cell Therapy. 2022 Oct 1; 44:s11-s12. Kuo KK, Layton LD, Lal LA, Al-Samkari AH, Bhatia BJ, Kosinski KP, Tong TB, Lynch LM, Uhlig UK, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    11. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study. Lancet. 2022 08 13; 400(10351):493-501. Kuo KHM, Layton DM, Lal A, Al-Samkari H, Bhatia J, Kosinski PA, Tong B, Lynch M, Uhlig K, Vichinsky EP. PMID: 35964609.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    12. Relationships among Physical Activity, Pain, and Bone Health in Youth and Adults with Thalassemia: An Observational Study. Thalass Rep. 2022 Sep; 12(3):90-100. Fung EB, Goldberg EK, Bambot S, Manzo R, Lal A. PMID: 37139496; PMCID: PMC10154047.
      View in: PubMed   Mentions:
    13. P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere. 2022 Aug 1; 6(Suppl):43-44. T. TC, A. AL, R. RB, T. TK, J. JK, J. JB, C. CT, K. KW, S. SS. .
      View in: Publisher Site   Mentions:
    14. S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY. HemaSphere. 2022 Jun 1; 6:171-172. Cappellini CM, Taher TA, Porter PJ, Kuo KK, Coates CT, Voskaridou VE, Forni FG, Perrotta PS, Khelif KA, Lal LA, Kattamis KA, Piga PA, Hermine HO, Holot HN, Lersch LF, Shetty SJ, Vodala VS, Zhang ZJ, Miteva MD, Viprakasit VV. .
      View in: Publisher Site   Mentions:
    15. PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere. 2022 Jun 1; 6(Suppl):2102-2103. Lal LA, Brown BR, Coates CT, Kalfa KT, Kwiatkowski KJ, Brevard BJ, Trenor TC, Wood WK, Sheth SS. .
      View in: Publisher Site   Mentions:
    16. P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ?ETA-THALASSEMIA. HemaSphere. 2022 Jun 1; 6(Suppl):1399-1400. Viprakasit VV, Cappellini CM, Porter PJ, Kuo KK, Coates CT, Voskaridou VE, Pinto PV, Tartaglione TI, Khelif KA, Lal LA, Kattamis KA, Piga PA, Hermine HO, Holot HN, Lersch LF, Shetty SJ, Zhang ZJ, Bueno BL, Giuseppi GA, Miteva MD, Taher TA. .
      View in: Publisher Site   Mentions:
    17. P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA. HemaSphere. 2022 Jun 1; 6(Suppl):1403-1404. Kuo KK, Layton LD, Lal LA, Al-Samkari AH, Bhatia BJ, Kosinski KP, Tong TB, Lynch LM, Uhlig UK, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    18. Noninvasive Prenatal Test for β-Thalassemia and Sickle Cell Disease Using Probe Capture Enrichment and Next-Generation Sequencing of DNA in Maternal Plasma. J Appl Lab Med. 2022 03 02; 7(2):515-531. Erlich HA, López-Peña C, Carlberg KT, Shih S, Bali G, Yamaguchi KD, Salamon H, Das R, Lal A, Calloway CD. PMID: 34849992.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. 28 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel) Gene Therapy in 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT): 7-Year Post-Infusion Follow-up of Phase 1/2 and Phase 3 Studies. Transplantation and Cellular Therapy. 2022 Mar 1; 28(3):s26-s27. Schneiderman SJ, Locatelli LF, Thompson TA, Kwiatkowski KJ, Porter PJ, Hongeng HS, Kulozik KA, Cavazzana CM, Sauer SM, Thrasher TA, Thuret TI, Lal LA, Rasko RJ, Yannaki YE, Schmidt SM, Du DL, Colvin CR, Walters WM. .
      View in: Publisher Site   Mentions:
    20. S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA. HemaSphere. 2022 Jan 31; 6(Suppl):8-9. Kuo KK, Layton LD, Lal LA, Al-Samkari AH, Bhatia BJ, Kosinski KP, Tong TB, Lynch LM, Uhlig UK, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    21. S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere. 2022 Jan 31; 6(Suppl):2-2. Lal LA, Brown BC, Coates CT, Kalfa KT, Kwiatkowski KJ, Brevard BJ, Trenor TC, Wood WK, Sheth SS. .
      View in: Publisher Site   Mentions:
    22. Nutrition in Thalassemia: A Systematic Review of Deficiency, Relations to Morbidity, and Supplementation Recommendations. J Pediatr Hematol Oncol. 2022 01 01; 44(1):1-11. Goldberg EK, Lal A, Fung EB. PMID: 34486568; PMCID: PMC8732300.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    23. Consensus statement for the perinatal management of patients with α thalassemia major. Blood Adv. 2021 12 28; 5(24):5636-5639. MacKenzie TC, Amid A, Angastiniotis M, Butler C, Gilbert S, Gonzalez J, Keller RL, Kharbanda S, Kirby-Allen M, Koenig BA, Kyono W, Lal A, Lianoglou BR, Norton ME, Ogasawara KK, Panchalee T, Rosner M, Schwab M, Thompson A, Waye JS, Vichinsky E. PMID: 34749399; PMCID: PMC8714716.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    24. Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia. N Engl J Med. 2022 02 03; 386(5):415-427. Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Thrasher AJ, Hongeng S, Sauer MG, Thuret I, Lal A, Algeri M, Schneiderman J, Olson TS, Carpenter B, Amrolia PJ, Anurathapan U, Schambach A, Chabannon C, Schmidt M, Labik I, Elliot H, Guo R, Asmal M, Colvin RA, Walters MC. PMID: 34891223.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCellsCTClinical Trials
    25. Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease. Blood. 2021 Nov 5; 138(Supplement 1):4162-4162. Lal LA, Brown BR, Coates CT, Kalfa KT, Kwiatkowski KJ, Brevard BJ, Potter PV, Wood WK, Sheth SS. .
      View in: Publisher Site   Mentions:
    26. Restoring Iron Homeostasis in Pts Who Achieved Transfusion Independence after Treatment with Betibeglogene Autotemcel Gene Therapy: Results from up to 7 Years of Follow-up. Blood. 2021 Nov 5; 138(Supplement 1):573-573. Thompson TA, Locatelli LF, Yannaki YE, Walters WM, Porter PJ, Hongeng HS, Kulozik KA, Sauer SM, Thrasher TA, Thuret TI, Lal LA, Cavazzana CM, Rasko RJ, Du DL, Colvin CR, Kwiatkowski KJ. .
      View in: Publisher Site   Mentions:
    27. Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia. Blood. 2021 Nov 5; 138(Supplement 1):576-576. Kuo KK, Layton LD, Lal LA, Al-Samkari AH, Bhatia BJ, Kosinski KP, Tong TB, Lynch LM, Uhlig UK, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    28. Improvement in Health-Related Quality of Life Following Treatment with Betibeglogene Autotemcel in Patients with Transfusion-Dependent ß-Thalassemia Enrolled in Phase 3 Studies. Blood. 2021 Nov 5; 138(Supplement 1):3085-3085. Kwiatkowski KJ, Locatelli LF, Walters WM, Porter PJ, Hongeng HS, Yannaki YE, Kulozik KA, Sauer SM, Thrasher TA, Thuret TI, Lal LA, Guo GR, Colvin CR, Gruppioni GK, Thompson TA. .
      View in: Publisher Site   Mentions:
    29. RESULTS FROM A PHASE 2 STUDY OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA. Hematology Transfusion and Cell Therapy. 2021 Oct 1; 43:s28. Kuo KK, Layton LD, Lal LA, Al-Samkari AH, Bhatia BJ, Tong TB, Lynch LM, Uhlig UK, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    30. The transfusion management of beta thalassemia in the United States. Transfusion. 2021 10; 61(10):3027-3039. Lal A, Wong T, Keel S, Pagano M, Chung J, Kamdar A, Rao L, Ikeda A, Puthenveetil G, Shah S, Yu J, Vichinsky E. PMID: 34453453; PMCID: PMC9292563.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    31. Pituitary iron and factors predictive of fertility status in transfusion dependent thalassemia. Haematologica. 2021 06 01; 106(6):1740-1744. Singer ST, Fischer R, Allen I, Lal A, Vichinsky E, Yuan Q, Wang ZJ. PMID: 33121232; PMCID: PMC8168491.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    32. 1 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-thalassemia) Gene Therapy in 60 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed for up to 6 Years Post-Infusion. . 2021 Mar 1; 27(3):s1. Hongeng HS, Thompson TA, Kwiatkowski KJ, Locatelli LF, Porter PJ, Rasko RJ, Cavazzana CM, Sauer SM, Thrasher TA, Thuret TI, Lal LA, Kulozik KA, Yannaki YE, Schmidt SM, Chen CY, Guo GR, Liu LW, Colvin CR, Walters WM. .
      View in: Publisher Site   Mentions:
    33. 122 Safety and Efficacy Outcomes in Pediatric Patients with Transfusion-Dependent ß-Thalassemia (TDT) Receiving Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-thalassemia) Gene Therapy in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies. . 2021 Mar 1; 27(3):s112-s114. Walters WM, Kwiatkowski KJ, Porter PJ, Hongeng HS, Yannaki YE, Kulozik KA, Sauer SM, Thrasher TA, Thuret TI, Lal LA, Guo GR, Liu LW, Colvin CR, Locatelli LF, Thompson TA. .
      View in: Publisher Site   Mentions:
    34. Challenges in chronic transfusion for patients with thalassemia. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):160-166. Lal A. PMID: 33275743; PMCID: PMC7727587.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    35. Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent ß-Thalassemia. Blood. 2020 Nov 5; 136(Supplement 1):52-54. Thompson TA, Kwiatkowski KJ, Porter PJ, Hongeng HS, Yannaki YE, Kulozik KA, Sauer SM, Thrasher TA, Thuret TI, Lal LA, Guo GR, Liu LW, Colvin CR, Walters WM, Locatelli LF. .
      View in: Publisher Site   Mentions:
    36. Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with ß-Thalassemia in the Believe Trial. Blood. 2020 Nov 5; 136(Supplement 1):47-48. Hermine HO, Cappellini CM, Taher TA, Coates CT, Viprakasit VV, Voskaridou VE, Lal LA, Liew LH, Perrotta PS, Khelif KA, Kattamis KA, Shetty SJ, Zhang ZG, Tian TY, Miteva MD, Zinger ZT, Tang TD, Backstrom BJ, Porter PJ. .
      View in: Publisher Site   Mentions:
    37. Response of Patients with Transfusion-Dependent ß-Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-Thalassemia) Gene Therapy Based on HBB Genotype and Disease Genetic Modifiers. Blood. 2020 Nov 5; 136(Supplement 1):1-3. Walters WM, Chui CD, Farrell FJ, Lal LA, Locatelli LF, Kwiatkowski KJ, Porter PJ, Sauer SM, Thuret TI, Hongeng HS, Kulozik KA, Thrasher TA, Yannaki YE, Yang YJ, Whitney WD, Petrusich PA, Colvin CR, Thompson TA. .
      View in: Publisher Site   Mentions:
    38. Zinc supplementation improves markers of glucose homeostasis in thalassaemia. Br J Haematol. 2020 08; 190(3):e162-e166. Fung EB, Ahmad T, Killilea DW, Hussain R, Lal A. PMID: 32488893.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    39. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. N Engl J Med. 2020 03 26; 382(13):1219-1231. Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A, BELIEVE Investigators. PMID: 32212518.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCTClinical Trials
    40. Interim Results from the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy (LentiGlobin) for the Treatment of Transfusion-Dependent ß-Thalassemia. Biology of Blood and Marrow Transplantation. 2020 Mar 1; 26(3):s87-s88. Schneiderman SJ, Thompson TA, Walters WM, Kwiatkowski KJ, Kulozik KA, Sauer SM, Porter PJ, Thuret TI, Hongeng HS, Lal LA, Thrasher TA, Yannaki YE, Elliot EH, Tao TG, Liu LW, Colvin CR, Locatelli LF. .
      View in: Publisher Site   Mentions:
    41. Taking Stock of Hemophilia, Immune Thrombocytopenia, and Bone Marrow Failure. Indian J Pediatr. 2020 02; 87(2):132-133. Bansal D, Lal A. PMID: 31900847.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. Iron Metabolism, Hemolytic Anemia, and Thalassemia. Indian J Pediatr. 2020 01; 87(1):56-57. Bansal D, Lal A. PMID: 31828597.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    43. Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent ß-Thalassemia and Either a ß0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene. Blood. 2019 Nov 13; 134(Supplement_1):815-815. Lal LA, Locatelli LF, Kwiatkowski KJ, Kulozik KA, Yannaki YE, Porter PJ, Thuret TI, Sauer SM, Elliot EH, Chen CY, Colvin CR, Thompson TA. .
      View in: Publisher Site   Mentions:
    44. Trends in Iron Overload over Past Two Decades: Results from the Natural History of Iron Burden Study with the SQUID Biosusceptometer. Blood. 2019 Nov 13; 134(Supplement_1):961-961. Lal LA, Fischer FR, Vichinsky VE, Weyhmiller WM. .
      View in: Publisher Site   Mentions:
    45. Thalassemia: Common Clinical Queries in Management. Indian J Pediatr. 2020 01; 87(1):75-81. Lal A, Bansal D. PMID: 31620986.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    46. Multicomponent Nutrient Bar Promotes Weight Loss and Improves Dyslipidemia and Insulin Resistance. Journal of the Academy of Nutrition and Dietetics. 2019 Oct 1; 119(10):a130. McKinnon MR, McCann MJ, Ames AB, Shigenaga SM, Lal LA, Suh SJ, Krauss KR, Gildengorin GG, Goldrich GA, Shenvi SS. .
      View in: Publisher Site   Mentions:
    47. Iron in Health and Disease: An Update. Indian J Pediatr. 2020 01; 87(1):58-65. Lal A. PMID: 31520313.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansPHPublic Health
    48. RESULTS FROM THE PHASE 3 NORTHSTAR-3 STUDY EVALUATING LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT ß-THALASSAEMIA AND A ß0 OR IVS-I-110 MUTATION AT BOTH ALLELES OF THE HBB GENE. HemaSphere. 2019 Jun 1; 3:21-22. Kulozik KA, Locatelli LF, Yannaki YE, Porter PJ, Thuret TI, Sauer SM, Lal LA, Kwiatkowski KJ, Elliot EH, Tao TG, Colvin CR, Thompson TA. .
      View in: Publisher Site   Mentions:
    49. Lentiglobin Gene Therapy for Patients with Transfusion-Dependent ß-Thalassemia (TDT): Results from the Phase 3 Northstar-2 and Northstar-3 Studies. Blood. 2018 Nov 29; 132(Supplement 1):1025-1025. Locatelli LF, Walters WM, Kwiatkowski KJ, Porter PJ, Sauer SM, Thuret TI, Hongeng HS, Kulozik KA, Lal LA, Thrasher TA, Yannaki YE, Elliot EH, Tao TG, Asmal AM, Thompson TA. .
      View in: Publisher Site   Mentions:
    50. Advances in Biomagnetic Liver Susceptometry Allow the Measurement of Liver Iron Concentration with a Room Temperature Sensor. Blood. 2018 Nov 29; 132(Supplement 1):4890-4890. Lal LA, Avrin AW, Kolotovska KV, Calvelli CL, Weyhmiller WM. .
      View in: Publisher Site   Mentions:
    51. Thalassemia Management Checklists: Quick Reference Guides to Reduce Disparities in the Care of Patients with Transfusion-Dependent Thalassemia. Blood. 2018 Nov 29; 132(Supplement 1):2233-2233. Lal LA, Sheth SS, Gilbert GS, Kwiatkowski KJ. .
      View in: Publisher Site   Mentions:
    52. Nutritional Deficiencies Are Common in Patients with Transfusion-Dependent Thalassemia and Associated with Iron Overload. J Food Nutr Res (Newark). 2018; 6(10):674-681. Goldberg EK, Neogi S, Lal A, Higa A, Fung E. PMID: 30569002; PMCID: PMC6296481.
      View in: PubMed   Mentions: 7  
    53. Transfusion practices and complications in thalassemia. Transfusion. 2018 12; 58(12):2826-2835. Lal A, Wong TE, Andrews J, Balasa VV, Chung JH, Forester CM, Ikeda AK, Keel SB, Pagano MB, Puthenveetil G, Shah SJ, Yu JC, Vichinsky EP. PMID: 30260477.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    54. A novel nutritional intervention improves lung function in overweight/obese adolescents with poorly controlled asthma: the Supplemental Nutrition in Asthma Control (SNAC) pilot study. FASEB J. 2018 Jul 19; fj201700338. Bseikri M, McCann JC, Lal A, Fong E, Graves K, Goldrich A, Block D, Gildengoren GL, Mietus-Snyder M, Shigenaga M, Suh J, Hardy K, Ames BN. PMID: 30024788.
      View in: PubMed   Mentions: 6     Fields:    
    55. Epidemiologic and clinical characteristics of nontransfusion-dependent thalassemia in the United States. Pediatr Blood Cancer. 2018 07; 65(7):e27067. Vichinsky E, Cohen A, Thompson AA, Giardina PJ, Lal A, Paley C, Cheng WY, McCormick N, Sasane M, Qiu Y, Kwiatkowski JL. PMID: 29637688.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    56. Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature. Prenat Diagn. 2016 Dec; 36(13):1242-1249. Kreger EM, Singer ST, Witt RG, Sweeters N, Lianoglou B, Lal A, Mackenzie TC, Vichinsky E. PMID: 27862048.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    57. Assessing Bone Quality Using Trabecular Bone Score in Patients with Hemoglobinopathies. Blood. 2016 Dec 2; 128(22):3629-3629. Cervantes CM, Lal LA, Marsh MA, Fung FE. .
      View in: Publisher Site   Mentions:
    58. Threshold Ferritin Values to Predict Control of Liver Iron Burden in Thalassemia. Blood. 2016 Dec 2; 128(22):4824-4824. Lal LA, Weyhmiller WM, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    59. Towards the Development of a Noninvasive Prenatal Test for Beta-Thalassemia: Utilization of Probe Capture Enrichment and Next Generation Sequencing. Blood. 2016 Dec 2; 128(22):3622-3622. Carlberg CK, Bose BN, Deng DJ, Lal LA, Erlich EH, Calloway CC. .
      View in: Publisher Site   Mentions:
    60. Implications of Low Zinc and Copper Levels As Well As Altered Iron Trafficking Proteins on Oxidant Stress in Patients with Transfusion Dependant Thalassemia. Blood. 2016 Dec 2; 128(22):1289-1289. Walter WP, Minkley MM, Curtis CC, Maeve MH, Morty MR, Ewing ES, Lal LA, Higa HA, Killilea KD, Pearson PT, Fung FE. .
      View in: Publisher Site   Mentions:
    61. 469 Implications of Altered Trace Minerals and Iron Trafficking Proteins on Oxidant Stress in Thalassemia. Free Radical Biology and Medicine. 2016 Nov 1; 100:s194-s195. Walter WP, Minkley MM, Curtis CC, Hodge HM, Morty MR, Ewing ES, Ennis EZ, Lal LA, Higa HA, Killilea KD, Pearson PT, Fung FE. .
      View in: Publisher Site   Mentions:
    62. Increased mitochondrial DNA deletions and copy number in transfusion-dependent thalassemia. JCI Insight. 2016 Aug 04; 1(12). Lal A, Gomez E, Calloway C. PMID: 27583305; PMCID: PMC5003175.
      View in: PubMed   Mentions: 4     Fields:    
    63. Assessment and treatment of pain in thalassemia. Ann N Y Acad Sci. 2016 03; 1368(1):65-72. Lal A. PMID: 27124110; PMCID: PMC4870117.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    64. 19. Nutrition for patients with thalassemia. Handbook of nutrition and diet in leukemia and blood disease therapy. 2016 Feb 9; 12:315-334. Fung FE, Schroepfer SC, Lal LA. .
      View in: Publisher Site   Mentions:
    65. Iron Level and Monocyte Morphology Predict TLR4 Expression and Reactive Oxygen Species Production Which Influences Chronic Inflammation in ß-Thalassemia. Blood. 2015 Dec 3; 126(23):950-950. Walter WP, Slater SN, Harmatz HP, Higa HA, Ng NV, Weyhmiller WM, Evans EP, Porter PJ, Sweeters SN, Price PJ, Killilea KD, Neumayr NL, Lal LA, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    66. The effect of iron chelators on bone health in patients with thalassemia. Bone Abstracts. 2015 Jun 9. Fung FE, Luo LN, Gildengorin GG, Lal LA. .
      View in: Publisher Site   Mentions:
    67. Zinc status affects glucose homeostasis and insulin secretion in patients with thalassemia. Nutrients. 2015 Jun 02; 7(6):4296-307. Fung EB, Gildengorin G, Talwar S, Hagar L, Lal A. PMID: 26043030; PMCID: PMC4488784.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    68. A multicomponent nutrient bar promotes weight loss and improves dyslipidemia and insulin resistance in the overweight/obese: chronic inflammation blunts these improvements. FASEB J. 2015 Aug; 29(8):3287-301. McCann JC, Shigenaga MK, Mietus-Snyder ML, Lal A, Suh JH, Krauss RM, Gildengorin GL, Goldrich AM, Block DS, Shenvi SV, McHugh TH, Olson DA, Ames BN. PMID: 25900806.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    69. Point-of-care end-tidal carbon monoxide reflects severity of hemolysis in sickle cell anemia. Pediatr Blood Cancer. 2015 May; 62(5):912-4. Lal A, Patterson L, Goldrich A, Marsh A. PMID: 25683629; PMCID: PMC4376621.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    70. Elevated End-Tidal Carbon Monoxide Concentration in Children with Sickle Cell Anemia. Blood. 2014 Dec 6; 124(21):1390-1390. Lal LA, Yen YK, Patterson PL, Goldrich GA, Marsh MA, Bhatnagar BA. .
      View in: Publisher Site   Mentions:
    71. Dietary Intake Insufficient to Support Nutritional Adequacy in Patients with Thalassemia. Blood. 2014 Dec 6; 124(21):1361-1361. Fung FE, Sushrita SN, Haines HD, Schroepfer SC, Lal LA. .
      View in: Publisher Site   Mentions:
    72. 138 Iron Overload and Hemolysis Modulate Monocytes and Inflammation in ß-Thalassemia. Free Radical Biology and Medicine. 2014 Nov 1; 76:s65. Slater SN, Harmatz HP, Higa HA, Ng NV, Weyhmiller WM, Evans EP, Porter PJ, Sweeters SN, Price PJ, Manji MA, Manocha MA, Killilea KD, Lal LA, Neumayr NL, Vichinsky VE, Walter WP. .
      View in: Publisher Site   Mentions:
    73. Mitochondrial Genome Changes As a Measure Of Iron-Induced Mitochondrial Stress In Transfusion-Dependent Thalassemia. Blood. 2013 Nov 15; 122(21):2256-2256. Gomez GE, Calloway CC, Lee LS, Kim KJ, Dhillon DN, Gildengorin GG, Lal LA. .
      View in: Publisher Site   Mentions:
    74. Association Of Cardiac Iron By T2* With Innate Immune Markers In Transfusion-Dependent Thalassemia Patients Undergoing Combined Chelation Therapy. Blood. 2013 Nov 15; 122(21):3450-3450. Walter WP, Higa HA, Ng NV, Weyhmiller WM, Slater SN, Evans EP, Porter PJ, Sweeters SN, Price PJ, Manji MA, Killilea KD, Lal LA, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    75. In-Accuracy Of Bone Density Measurements By DXA In Patients With Hemoglobinopathies and Iron Overload. Blood. 2013 Nov 15; 122(21):966-966. Allard AH, Weyhmiller WM, Lal LA, Fung FE. .
      View in: Publisher Site   Mentions:
    76. Innate Immune Cell Expression of Pattern Recognition Receptors From ß-Thalassemia Patients During Intensive Combination Chelation Therapy. Blood. 2012 Nov 16; 120(21):1025-1025. Walter WP, Harmatz HP, Higa HA, Ng NV, Weyhmiller WM, Evans EP, Porter PJ, Sweeters SN, Price PJ, Manji MA, Killilea KD, Lal LA, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    77. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis. 2013 Feb; 50(2):99-104. Lal A, Porter J, Sweeters N, Ng V, Evans P, Neumayr L, Kurio G, Harmatz P, Vichinsky E. PMID: 23151373; PMCID: PMC3592978.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    78. A nutrient-dense, high-fiber, fruit-based supplement bar increases HDL cholesterol, particularly large HDL, lowers homocysteine, and raises glutathione in a 2-wk trial. FASEB J. 2012 Aug; 26(8):3515-27. Mietus-Snyder ML, Shigenaga MK, Suh JH, Shenvi SV, Lal A, McHugh T, Olson D, Lilienstein J, Krauss RM, Gildengoren G, McCann JC, Ames BN. PMID: 22549511; PMCID: PMC3405270.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    79. Abstract P217: Metabolic Effects of a Nutrient-Dense High Fiber Supplement. Circulation. 2012 Mar 13; 125(suppl_10). Mietus-Snyder MM, Shigenaga SM, Suh SJ, Shenvi SS, Lal LA, McHugh MT, Olson OD, McCann MJ, Krauss KR, Ames AB. .
      View in: Publisher Site   Mentions:
    80. Exploring Vertebral Height Deficits in Patients with Thalassemia and Sickle Cell Disease,. Blood. 2011 Nov 18; 118(21):3198-3198. Fung FE, Reget RK, Haines HD, Sawyer SA, Lal LA. .
      View in: Publisher Site   Mentions:
    81. Oxidative Stress and Reproductive Capacity in Iron Overload Thalassemia Major Women. Blood. 2011 Nov 18; 118(21):2155-2155. Singer SS, Vichinsky VE, Cedars CM, Gildengorin GG, Suh SJ, Lal LA. .
      View in: Publisher Site   Mentions:
    82. Treatment of vitamin D deficiency in transfusion-dependent thalassemia. Am J Hematol. 2011 Oct; 86(10):871-3. Fung EB, Aguilar C, Micaily I, Haines D, Lal A. PMID: 21818763.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    83. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med. 2011 Feb 24; 364(8):710-8. Lal A, Goldrich ML, Haines DA, Azimi M, Singer ST, Vichinsky EP. PMID: 21345100.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansPHPublic Health
    84. Association of chromosome damage detected as micronuclei with hematological diseases and micronutrient status. Mutagenesis. 2011 Jan; 26(1):57-62. Lal A, Ames BN. PMID: 21164183; PMCID: PMC3107612.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    85. Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia. Blood. 2010 Nov 19; 116(21):4269-4269. Lal LA, Sweeters SN, Ng NV, Foote FD, Evans EP, Neumayr NL, Kurio KG, Harmatz HP, Porter PJ, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    86. Reduced Physical Activity In Adult and Pediatric Patients with Thalassemia. Blood. 2010 Nov 19; 116(21):5174-5174. Garie´py GC, Lal LA, Fung FE. .
      View in: Publisher Site   Mentions:
    87. Longitudinal Follow-up From Newborn Screening Reveals Deletional Hemoglobin H Disease and Hemoglobin H Constant Spring Disease Are Distinct Thalassemia Syndromes. Blood. 2010 Nov 19; 116(21):4260-4260. Lal LA, Goldrich GM, Foote FD, Azimi AM, Singer SS, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    88. A Simple Regimen to Correct Vitamin D Deficiency In Transfusion-Dependent Thalassemia with High-Dose Ergocalciferol. Blood. 2010 Nov 19; 116(21):4261-4261. Lal LA, Micaily MI, Foote FD, Fung FE. .
      View in: Publisher Site   Mentions:
    89. Sickle Cell Disease. Postgraduate Haematology. 2010 Oct 28; 109-125. Lal LA, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    90. Heightened Sulfur Amino Acid Oxidation in Plasma and Erythrocytes in ß-Thalassemia Major. Blood. 2009 Nov 20; 114(22):4065-4065. Agrawal AA, Suh SJ, Ames AB, Vichinsky VE, Lal LA. .
      View in: Publisher Site   Mentions:
    91. Safety of Combined Chelation Therapy with Deferasirox and Deferoxamine in Transfusion-Dependent Thalassemia. Blood. 2009 Nov 20; 114(22):2021-2021. Lal LA, Sweeters SN, Herz HM, Foote FD, Neumayr NL, Kurio KG, Harmatz HP, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    92. Clinical assay of four thiol amino acid redox couples by LC-MS/MS: utility in thalassemia. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Oct 15; 877(28):3418-27. Suh JH, Kim R, Yavuz B, Lee D, Lal A, Ames BN, Shigenaga MK. PMID: 19616487; PMCID: PMC3077474.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    93. Body Composition and Its Relationship to Growth and Bone Mass in Patients with Thalassemia. Blood. 2008 Nov 16; 112(11):3890-3890. Fung FE, Xu XY, Kwiatkowski KJ, Singer SS, Lal LA, Vogiatzi VM, Olivieri ON, Neufeld NE, Vichinsky VE, Giardina GP. .
      View in: Publisher Site   Mentions:
    94. Hemoglobin H-Constant Spring in North America: A Common Alpha Thalassemia with Frequent Complications. Blood. 2008 Nov 16; 112(11):1880-1880. Singer ST, Kim KH, Olivieri ON, Kwiatkowski KJ, Lal LA, Coates CT, Carson CS, Cunningham CM, Giardina GP, Mueller MB, Quinn QC, Vichinsky VE, Network NT. .
      View in: Publisher Site   Mentions:
    95. Lipoic acid and acetyl-carnitine reverse iron-induced oxidative stress in human fibroblasts. Redox Rep. 2008; 13(1):2-10. Lal A, Atamna W, Killilea DW, Suh JH, Ames BN. PMID: 18284845.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    96. Anti-Oxidant Treatment with a-Lipoic Acid and Acetyl L-Carnitine in Hemoglobinopathies. Blood. 2007 Nov 16; 110(11):3799-3799. Lal LA, Suh SJ, Atamna AW, Canty CB, Hagar HW, Vichinsky VE, Kuypers KF, Ames AB. .
      View in: Publisher Site   Mentions:
    97. Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer. 2006 Dec; 47(7):901-6. Lal A, Fung EB, Pakbaz Z, Hackney-Stephens E, Vichinsky EP. PMID: 16317761.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    98. Bone mineral density in children and young adults with beta-thalassemia major conventionally treated—RESPONSE. Pediatric Blood & Cancer. 2006 Jul 1; 47(1):115-115. Lal LA, Fung FE, Pakbaz PZ, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    99. Increased Chromosomal Breaks in Sickle Cell Disease as Evidenced by the Presence of Micronuclei in Erythrocytes. Blood. 2005 Nov 16; 106(11):3807-3807. Lal LA, Bhagat BA, Atamna AW, Offer OT, Vichinsky VE, Kuypers KF, Ames AB. .
      View in: Publisher Site   Mentions:
    100. Efficacy of Alpha-Lipoic Acid in Iron-Induced Oxidative Stress. Blood. 2005 Nov 16; 106(11):3599-3599. Lal LA, Suh SJ, Ames AB. .
      View in: Publisher Site   Mentions:
    101. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2005 Sep 20; 23(27):6474-80. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK. PMID: 16116154.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    102. Sickle Cell Disease. Postgraduate Haematology. 2005 Mar 30; 104-118. Lal LA, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    103. Measuring chromosome breaks in patients with thalassemia. Ann N Y Acad Sci. 2005; 1054:439-44. Offer T, Bhagat A, Lal A, Atamna W, Singer ST, Vichinsky EP, Kuypers FA, Ames BN. PMID: 16339694.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    104. Evaluation of Bone Mineral Density in Children with Sickle Cell Anemia. Blood. 2004 Nov 16; 104(11):106-106. Lal LA, Fung FE, Kammen KB, Pakbaz PZ, Sweeters SN, Hackney-Stevens HE, Quirolo QK, Vichinsky VE. .
      View in: Publisher Site   Mentions:
    105. The role of fetal hemoglobin-enhancing agents in thalassemia. Semin Hematol. 2004 Oct; 41(4 Suppl 6):17-22. Lal A, Vichinsky E. PMID: 15534853.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    Ashutosh's Networks
    Concepts (203)
    Derived automatically from this person's publications.
    _
    Co-Authors (28)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _